Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

NovaBay Pharmaceuticals

AMEX:NBY
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NBY
AMEX
$23M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic anti-infective products for the eye care market in the United States, China, and internationally. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • NovaBay Pharmaceuticals has significant price volatility in the past 3 months.
NBY Share Price and Events
7 Day Returns
6.6%
AMEX:NBY
5.9%
US Pharmaceuticals
-2.8%
US Market
1 Year Returns
-24.3%
AMEX:NBY
-6.3%
US Pharmaceuticals
-15.9%
US Market
NBY Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NovaBay Pharmaceuticals (NBY) 6.6% 58.5% 28.4% -24.3% -78.4% -96.2%
US Pharmaceuticals 5.9% -7.7% -11.3% -6.3% 5.5% 1.3%
US Market -2.8% -18.8% -24% -15.9% 2.8% 13.3%
1 Year Return vs Industry and Market
  • NBY underperformed the Pharmaceuticals industry which returned -6.3% over the past year.
  • NBY underperformed the Market in United States of America which returned -15.9% over the past year.
Price Volatility
NBY
Industry
5yr Volatility vs Market

Value

 Is NovaBay Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NovaBay Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $0.81.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NovaBay Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NovaBay Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:NBY PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.48
AMEX:NBY Share Price ** AMEX (2020-04-03) in USD $0.81
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.57x
United States of America Market PE Ratio Median Figure of 2,947 Publicly-Listed Companies 12.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NovaBay Pharmaceuticals.

AMEX:NBY PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:NBY Share Price ÷ EPS (both in USD)

= 0.81 ÷ -0.48

-1.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NovaBay Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • NovaBay Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does NovaBay Pharmaceuticals's expected growth come at a high price?
Raw Data
AMEX:NBY PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
60%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.9x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.88x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NovaBay Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NovaBay Pharmaceuticals's assets?
Raw Data
AMEX:NBY PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.03
AMEX:NBY Share Price * AMEX (2020-04-03) in USD $0.81
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 2.16x
United States of America Market PB Ratio Median Figure of 5,146 Publicly-Listed Companies 1.2x
AMEX:NBY PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:NBY Share Price ÷ Book Value per Share (both in USD)

= 0.81 ÷ 0.03

23.26x

* Primary Listing of NovaBay Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NovaBay Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess NovaBay Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. NovaBay Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NovaBay Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NovaBay Pharmaceuticals expected to grow at an attractive rate?
  • NovaBay Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • NovaBay Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • NovaBay Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
AMEX:NBY Future Growth Rates Data Sources
Data Point Source Value (per year)
AMEX:NBY Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 60%
AMEX:NBY Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 34.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.2%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:NBY Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:NBY Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 21 1 1
2021-12-31 13 -6 -5 2
2020-12-31 10 -7 -7 2
2020-04-05
AMEX:NBY Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -8 -10
2019-09-30 9 -8 -8
2019-06-30 10 -9 -10
2019-03-31 11 -8 -9
2018-12-31 13 -6 -7
2018-09-30 15 -7 -4
2018-06-30 16 -5 -5
2018-03-31 17 -5 -6
2017-12-31 18 -6 -7
2017-09-30 16 -4 -10
2017-06-30 15 -8 -11
2017-03-31 14 -9 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NovaBay Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • NovaBay Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:NBY Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from NovaBay Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:NBY Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.03 0.03 0.03 1.00
2021-12-31 -0.15 -0.09 -0.21 2.00
2020-12-31 -0.26 -0.22 -0.29 2.00
2020-04-05
AMEX:NBY Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.48
2019-09-30 -0.44
2019-06-30 -0.55
2019-03-31 -0.50
2018-12-31 -0.39
2018-09-30 -0.27
2018-06-30 -0.34
2018-03-31 -0.36
2017-12-31 -0.48
2017-09-30 -0.64
2017-06-30 -0.78
2017-03-31 -0.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NovaBay Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess NovaBay Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NovaBay Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NovaBay Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NovaBay Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NovaBay Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare NovaBay Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NovaBay Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
NovaBay Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NovaBay Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:NBY Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.60 -10.49 13.86 0.18
2019-09-30 8.52 -8.27 15.31 0.27
2019-06-30 10.05 -9.53 17.13 0.27
2019-03-31 11.05 -8.58 18.74 0.30
2018-12-31 12.51 -6.55 18.62 0.26
2018-09-30 15.20 -4.48 18.73 0.30
2018-06-30 16.15 -5.39 19.76 0.39
2018-03-31 17.48 -5.54 20.54 0.39
2017-12-31 18.23 -7.40 22.35 0.41
2017-09-30 15.99 -9.84 22.69 0.42
2017-06-30 15.34 -11.13 21.94 0.29
2017-03-31 13.88 -12.09 20.98 0.50
2016-12-31 11.90 -13.15 19.04 1.37
2016-09-30 9.46 -15.71 19.92 2.35
2016-06-30 7.22 -17.21 19.78 3.91
2016-03-31 5.56 -19.41 19.89 4.99
2015-12-31 4.38 -18.97 18.53 5.73
2015-09-30 3.24 -19.24 15.10 6.94
2015-06-30 2.19 -18.21 12.30 7.69
2015-03-31 1.30 -16.27 9.70 11.09
2014-12-31 1.05 -15.19 7.99 9.48
2014-09-30 1.07 -14.86 6.53 19.54
2014-06-30 2.02 -14.49 6.15 17.23
2014-03-31 2.75 -15.60 6.49 12.46
2013-12-31 3.48 -16.04 6.34 12.46
2013-09-30 4.08 -14.26 6.91
2013-06-30 6.62 -10.33 6.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NovaBay Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NovaBay Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NovaBay Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NovaBay Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NovaBay Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NovaBay Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NovaBay Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NovaBay Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NovaBay Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NovaBay Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NovaBay Pharmaceuticals Company Filings, last reported 3 months ago.

AMEX:NBY Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 0.97 2.61 6.94
2019-09-30 3.51 3.05 9.02
2019-06-30 1.67 2.76 3.67
2019-03-31 1.13 2.25 2.93
2018-12-31 4.95 0.00 3.18
2018-09-30 6.06 0.00 5.21
2018-06-30 7.43 0.00 6.83
2018-03-31 8.87 0.00 8.34
2017-12-31 2.59 0.00 3.20
2017-09-30 1.83 0.00 6.08
2017-06-30 3.21 0.00 5.72
2017-03-31 4.36 0.00 7.40
2016-12-31 7.10 0.00 9.51
2016-09-30 6.72 0.00 9.43
2016-06-30 -2.47 0.52 3.79
2016-03-31 -7.30 3.06 1.43
2015-12-31 -5.10 1.66 2.39
2015-09-30 0.23 0.00 3.38
2015-06-30 4.90 0.00 7.21
2015-03-31 2.15 0.00 5.60
2014-12-31 1.85 0.00 5.43
2014-09-30 5.69 0.00 9.14
2014-06-30 9.22 0.00 11.57
2014-03-31 11.84 0.00 15.17
2013-12-31 8.52 0.00 13.05
2013-09-30 5.42 0.00 10.82
2013-06-30 7.21 0.00 11.41
  • NovaBay Pharmaceuticals's level of debt (268.3%) compared to net worth is high (greater than 40%).
  • Unable to establish if NovaBay Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NovaBay Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • NovaBay Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.2% each year.
X
Financial health checks
We assess NovaBay Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NovaBay Pharmaceuticals has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NovaBay Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NovaBay Pharmaceuticals dividends.
If you bought $2,000 of NovaBay Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NovaBay Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NovaBay Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:NBY Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1936 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2.1%
United States of America Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AMEX:NBY Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NovaBay Pharmaceuticals has not reported any payouts.
  • Unable to verify if NovaBay Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NovaBay Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NovaBay Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NovaBay Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NovaBay Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NovaBay Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NovaBay Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Justin Hall
COMPENSATION $572,159
AGE 41
TENURE AS CEO 1.1 years
CEO Bio

Mr. Justin M. Hall, Esq. has been General Counsel at NovaBay Pharmaceuticals, Inc. since December 2015, Corporate Secretary since July 16, 2017 and President and Chief Executive Officer since June 17, 2019 and also serves as its Chief Compliance Officer. Mr. Hall served as Interim President and Chief Executive Officer of at NovaBay Pharmaceuticals, Inc. since March 8, 2019 until June 17, 2019. Mr. Hall served as lead in-house counsel at NovaBay Pharmaceuticals, Inc. since beginning in February 2013 and Senior Vice President since December 2015 until March 8, 2019. Mr. Hall joined NovaBay in February 2013. He acts as the Chief Legal Counsel overseeing equity fundraising, NovaBay Pharmaceuticals’ listing on the New York Stock Exchange, its patent portfolio and all aspects of corporate compliance. Prior to joining NovaBay, Mr. Hall worked as Corporate Counsel at Accuray Incorporated, a radiation oncology company, which he joined in October 2006, where he reported directly to the General Counsel and provided substantive legal advice on a broad range of complex legal matters with a focus on employment, corporate compliance and corporate governance. Mr. Hall also works as an investment advisor and attorney for the 401(k) Resource Center, which he founded in January 2009, which helps Plan Sponsors manage their retirement plans by providing legal advice. Mr. Hall’s prior experience also includes serving as an investment advisor at Sagemark Consulting from 2000 to 2006 and a stockbroker at First Security Van Kasper from 1998 to 2001. Mr. Hall received a B.A. in Business Administration and Management from the University of California, San Diego and a J.D. from the University Of San Diego School Of Law.

CEO Compensation
  • Justin's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Justin's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the NovaBay Pharmaceuticals management team in years:

1.1
Average Tenure
64
Average Age
  • The average tenure for the NovaBay Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Justin Hall

TITLE
President
COMPENSATION
$572K
AGE
41
TENURE
1.1 yrs

Lynn Christopher

TITLE
Interim CFO & Treasurer
AGE
64
TENURE
0.1 yrs

David Stroman

TITLE
Senior VP of Ophthalmic Product Development & Chair of Ophthalmology Advisory Board
AGE
74
TENURE
8.5 yrs
Board of Directors Tenure

Average tenure and age of the NovaBay Pharmaceuticals board of directors in years:

5.7
Average Tenure
72
Average Age
  • The tenure for the NovaBay Pharmaceuticals board of directors is about average.
Board of Directors

Paul Freiman

TITLE
Chairman & Lead Independent Director
COMPENSATION
$104K
AGE
84
TENURE
1.1 yrs

David Stroman

TITLE
Senior VP of Ophthalmic Product Development & Chair of Ophthalmology Advisory Board
AGE
74

Jeff Zheng

TITLE
Independent Director
AGE
63
TENURE
0.6 yrs

Richard Lindstrom

TITLE
Member of Ophthalmic Advisory Board
AGE
71
TENURE
5.7 yrs

Terry Kim

TITLE
Member of Ophthalmic Advisory Board
TENURE
5.7 yrs

Francis Mah

TITLE
Member of Ophthalmic Advisory Board
TENURE
5.7 yrs

Steve Wilmarth

TITLE
Member of Ophthalmic Advisory Board
TENURE
9.3 yrs

Katy Najafi-Tagol

TITLE
Member of Ophthalmic Advisory Board
TENURE
9.3 yrs

James Branch

TITLE
Member of Ophthalmic Advisory Board
AGE
72
TENURE
7.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Jun 19 Sell Tian Tian Limited Company 11. Jun 19 11. Jun 19 -24,326 $4.04 $-98,277
14. Jun 19 Sell Jianping Fu Individual 11. Jun 19 11. Jun 19 -380,954 $3.84 $-1,462,863
13. Jun 19 Sell Mijia Wu Individual 10. Jun 19 11. Jun 19 -63,492 $4.04 $-160,793
X
Management checks
We assess NovaBay Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NovaBay Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Does NovaBay Pharmaceuticals Inc (NYSEMKT:NBY) Compare To The Healthcare Sector?

operates in the healthcare industry,. … The environment facing pharmaceuticals companies, particularly, remains challenging, driven by a more demanding healthcare agenda … The global need for innovative, cost-effective medicines continues to rise, whilst regulators and healthcare providers require more transparency and proven effectiveness

Simply Wall St -

NovaBay Pharmaceuticals Inc (NYSEMKT:NBY): Are Analysts Optimistic?

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. … The US$44.43m market-cap company’s loss lessens since it announced a -US$7.40m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -US$5.54m, as it approaches breakeven. … See our latest analysis for NovaBay Pharmaceuticals

Simply Wall St -

Want To Invest In NovaBay Pharmaceuticals Inc (NYSEMKT:NBY)? Here's How It Performed Lately

AMEX:NBY Income Statement May 22nd 18 We can further analyze NovaBay Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years NovaBay Pharmaceuticals's top-line has increased by 10.68% on average, signalling that the company is in a high-growth phase with expenses racing ahead revenues, leading to annual losses. … Inspecting growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 11.92% over the past year, and a more muted 9.59% over the last five years.

Simply Wall St -

Company Info

Description

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Details
Name: NovaBay Pharmaceuticals, Inc.
NBY
Exchange: AMEX
Founded: 2000
$22,688,556
28,010,564
Website: http://www.novabay.com
Address: NovaBay Pharmaceuticals, Inc.
2000 Powell Street,
Suite 1150,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX NBY Common Stock NYSE MKT LLC US USD 26. Oct 2007
Number of employees
Current staff
Staff numbers
27
NovaBay Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 05:44
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.